LACOSAMIDE

Post-LOE

lacosamide

ANDAINTRAVENOUSSOLUTION
Approved
Sep 2022
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

elucidated. In vitro electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.

Clinical Trials (5)

NCT04519645Phase 2Terminated

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures

Started Mar 2021
29 enrolled
Electroencephalographic Neonatal SeizuresEpilepsy
NCT04627285Phase 3Completed

A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment

Started Dec 2020
48 enrolled
Epilepsy
NCT03204474Phase 1Completed

A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects

Started Jun 2017
30 enrolled
Healthy Male Chinese Volunteers
NCT02710890Phase 2/3Completed

Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.

Started May 2017
103 enrolled
Epilepsy
NCT03086382Phase 1Completed

A Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects

Started Feb 2017
24 enrolled
Healthy Male Volunteers